12:00 AM
 | 
Sep 17, 2012
 |  BC Week In Review  |  Company News  |  Deals

WuXi PharmaTech, AstraZeneca deal

AstraZeneca's MedImmune LLC biologics unit formed a 50/50 JV with WuXi to develop and commercialize MedImmune's MEDI5117 in China for autoimmune and inflammatory diseases. The mAb against IL-6 is in...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >